The Readout Loud

420: Democrats’ midterm victory, and a questionable fertility procedure

How will the midterm results affect drug pricing policy? What is the fate of the Food and Drug Administration? And why are women traveling to fertility clinics abroad? O

419: Assessing Merck and Moderna's mRNA cancer vaccine

What is Adam doing in Spain? How did doctors react to detailed data on Merck and Moderna's mRNA cancer vaccine? And what are the next big advances in oncology? On this w

418: Remembering STAT’s Helen Branswell

Helen Branswell was a renowned infectious disease reporter who earned the respect and admiration of experts and public health officials with her authoritative, prescient

417: Hospitals' next lucrative bet — longevity clinics

Longevity medicine is now estimated to be a multitrillion dollar industry. But what are people paying for, and does it work? On this week's episode of “The Readout LOUD,

416: NIH funding uncertainty thwarts U.S. researchers

How has the National Institutes of Health been spending its budget? Why are biotech investors feeling gloomy? And what is the most quintessential Boston movie? We discus

415: Mistrust in science and a juicy gene-editing lawsuit

On this week’s episode of "The Readout LOUD": Why have so many Americans lost trust in science? And how have our policy leaders fueled that mistrust? We speak to STAT’s n

The FDA's Overton era, and dispatches from Shanghai

"The Readout LOUD" is going international this week. STAT's Jason Mast joins the podcast from Shanghai, where he's digging into what the rise of Chinese drug development

Definium's new psychedelics data, and a reprieve for international scientists

International researchers got a reprieve in the courts this week. But many are still considering leaving the states for opportunities elsewhere. What does that mean for t

Why two promising heart drugs flopped and what's next

On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease

411: Capricor's data clash and a fugitive in the C-suite

Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies?

410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing

What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a want

409: Predicting biotech clinical trials & a new Alzheimer's drug controversy

On this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatmen

408: Whistleblower takes on health insurance and FDA commissioner candidates

Why does getting family health insurance through a job cost as much as buying a new car? How did a whistleblower take on an insurance contractor? And who might be the new

407: The mysterious case of Eli Lilly's obesity drug

Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good in

406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises

This week: New hope for people living with Huntington’s disease, and a report card on RFK Jr.’s effort to remake health in America.  The Food and Drug Administration rev

405: An obesity drug deep-dive, and peptides move mainstream

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration al

404: What RevMed's pancreatic cancer drug meant for one patient

Why did oncologists give a standing ovation to a data presentation on Revolution Medicines' pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly

403: Biotech exec Jeremy Levin on the industry's strategic turning point

On this week’s episode of “The Readout LOUD,” we chat with longtime biotech executive Jeremy Levin about his new book, “Biotech in the Balance: Saving a Strategic Industr

402: Guarding biotech from China and big bets in longevity

On this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. The

401: Makary’s departure and Cassidy’s tenuous Senate seat

This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he is leaving, which